Lyell Immunopharma, Inc. (LYEL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Lyell Immunopharma is a late-stage clinical cell therapy company focused on developing autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company's lead asset is rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma (LBCL). In November 2025 (subsequent to the period end), the company acquired exclusive global rights to LYL273, a GCC-targeted CAR T-cell therapy for metastatic colorectal cancer (mCRC).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $15 | $34 | $30 | $50 |
| Net Loss | $(38,846) | $(44,583) | $(133,725) | $(151,059) |
| Diluted EPS | $(2.13) | $(3.48) | $(8.38) | $(11.83) |
| Operating Expenses | $37,268 | $50,539 | $141,790 | $157,658 |
| Cash & Equivalents | $123,575 | $105,597 | $123,575 | $105,597 |
| Marketable Securities | $196,049 | $264,930 | $196,049 | $264,930 |
| Total Liquidity | $319,624 | $370,527 | $319,624 | $370,527 |
Note: Revenue is nominal, derived from sublease income and other operating activities. The company has no approved products for sale.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by $5.7 million in Q3 2025 compared to Q3 2024, and by $17.3 million on a year-to-date basis. This improvement is primarily driven by reduced operating expenses.
- Expense Reductions: Research and Development (R&D) expenses decreased by $11.3 million in Q3 and $16.5 million YTD, attributed to lower headcount, reduced collaboration costs, and decreased depreciation following prior asset impairments. General and Administrative (G&A) expenses also declined due to lower stock-based compensation and legal fees.
- Financing Activity: In July 2025, the company completed a Securities Purchase Agreement (SPA) raising approximately $50.0 million in gross proceeds. This included the issuance of 3.75 million shares and a put/call option for an additional $50.0 million upon milestone achievement.
- Stock Split: A 1-for-20 reverse stock split was effected on May 30, 2025. All historical share and per-share data have been retroactively adjusted.
- Impairment Charges: The company recognized a $1.4 million impairment of long-lived assets in the first nine months of 2025 related to the closure of its West Hills, Los Angeles facility following the transition of manufacturing to its LyFE Manufacturing Center in Bothell, Washington.
Guidance, Outlook, and Risks
- Clinical Progress:
- Ronde-cel: The pivotal PiNACLE trial (3L+ setting) is ongoing. The company announced the initiation of the PiNACLE-H2H Phase 3 head-to-head trial (2L setting) with first patient enrollment expected in early 2026. Recent data showed an 88% overall response rate in the 3L+ setting.
- LYL273: Following the November 2025 acquisition, the company plans to transition manufacturing to its LyFE facility. The U.S. Phase 1 trial continues to enroll.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($319.6 million as of Sept 30, 2025) are sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional capital in the future to complete clinical development and commercialization.
- Key Risks:
- Capital Requirements: Continued substantial losses and the need for future financing, which may result in dilution.
- Clinical Uncertainty: Failure of product candidates to demonstrate safety/efficacy in pivotal trials or obtain regulatory approval.
- Manufacturing: Risks associated with scaling production and transitioning LYL273 manufacturing to the LyFE facility.
- Market Volatility: The company previously faced Nasdaq delisting risks due to low stock price, which was temporarily resolved via the reverse stock split.
Investor Verification Checklist
- Runway Validation: Verify the sufficiency of the $319.6 million liquidity position against the projected burn rate for the PiNACLE-H2H trial and LYL273 development.
- SPA Terms: Review the specific milestones triggering the additional $50.0 million put/call option under the July 2025 Securities Purchase Agreement.
- Manufacturing Transition: Confirm the timeline and regulatory status for transitioning LYL273 manufacturing from the licensor to Lyell's LyFE Manufacturing Center.
- Contingent Liabilities: Monitor the fair value changes of success payment liabilities to Fred Hutch and Stanford, which fluctuate with stock price and impact non-cash expenses.
- Subsequent Events: Review the terms of the November 2025 acquisition of LYL273, including the $40 million upfront payment and potential future milestone obligations totaling up to $675 million.